Earnings Summary

Sanofi’s revenue jumped 11.49% since last year same period to $14157Mn in the Q3 2024. On a quarterly growth basis, Sanofi has generated 24.4% jump in its revenue since last 3-months.

Sanofi’s net profit jumped 11.49% since last year same period to $2815Mn in the Q3 2024. On a quarterly growth basis, Sanofi has generated 152.92% jump in its net profits since last 3-months.

Sanofi’s net profit margin fell -0% since last year same period to 19.88% in the Q3 2024. On a quarterly growth basis, Sanofi has generated 103.31% jump in its net profit margins since last 3-months.

Sanofi’s price-to-earnings ratio after this Q3 2024 earnings stands at 25.26.

Sanofi’s earning per share (EPS) estimates for the current quarter stand at 1.38 - a 60.77% jump from last quarter’s estimates.

Sanofi’s earning per share (EPS) estimates for the current year stand at 1.38.

Sanofi’s earning per share (EPS) fell -43.32% since last year same period to 1.57 in the Q3 2024. This indicates that the Sanofi has generated -43.32% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Sanofi’s return on assets (ROA) stands at 0.04.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Sanofi’s return on equity (ROE) stands at 0.06.